Dear Richard,
On behalf of our BUPE2024-Buprenorphine in Medicine conference co-chairs, Dr. Mellar Davis and Dr. Mary Lynn McPherson, we are reaching out to recruit additional presentations for the following specific topics to round out our BUPE2024 educational site. If you have expertise in these areas, we would appreciate an abstract for a 30-60 minute recorded or live presentation. We also have a section for video posters for late breaking research on all buprenorphine topics.
BUPE2024 Questions
Main Questions:
- Why is buprenorphine not covered by health insurance? Why is it difficult to get insurance coverage?
- Why is buprenorphine excluded from health insurance formularies of prescription drugs for pain management?
- What is the DEA’s perspective on buprenorphine being excluded from formularies?
-
What is the addiction medicine community’s perspective on prescribing buprenorphine for addiction treatment?
- What challenges do pharmacists face filling buprenorphine prescriptions?
- What are the implications of converting patients from buprenorphine treatment to other opioids?
- What is the safest way to wean patients off buprenorphine treatment?
- Should there be a front-line drug for pain management instead of initially prescribing potentially addictive meds like oxycodone? Buprenorphine?!
- How does buprenorphine compare to other opioids for pain management and addiction treatment?
- How does buprenorphine compare to other opioids regarding tolerance to achieve the same analgesic effect?
- What are the clinical usages/aspects of buprenorphine? Clinical pain management vs. addiction.
- Are there advantages or disadvantages of combining buprenorphine with other opioids?
- What is the best way to convert to buprenorphine? 1-Transition to TD buprenorphine, 2- Microdose?
- Myths regarding buprenorphine.
- Why is buprenorphine used on the street?
- Rotations from buprenorphine to other opioids.
- Buprenorphine versus naloxone in reversing opioid-induced respiratory depression, is it time for consideration?
- Utilization of buprenorphine in hospice and palliative medicine.
- The use of AI for decision support when prescribing buprenorphine and other opioids.
Other ideas/topics:
- Issues on the fringe
- Practical aspects
- Conversion ratios
- Educating other physicians, families/patients
- Buprenorphine vs. another opioid
- Infographics
- Myths of buprenorphine
- A session of submitted questions that get asked on a regular basis.
Presentation subjects we’d like to pursue:
- Health insurance
- Clinical
- Pharmacist
- Basic pharmacology
- Psychiatry
- DEA
- Basic science
- Opioid ethics
- Sons of buprenorphine
Please submit your presentation abstract by Monday, July 31, 2024, to help expand knowledge on buprenorphine's diverse role in pain management and addiction treatment. Thank You!
|